Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2021

01-12-2021 | COVID-19 | Research article

A network-based model to explore the role of testing in the epidemiological control of the COVID-19 pandemic

Authors: Yapeng Cui, Shunjiang Ni, Shifei Shen

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Testing is one of the most effective means to manage the COVID-19 pandemic. However, there is an upper bound on daily testing volume because of limited healthcare staff and working hours, as well as different testing methods, such as random testing and contact-tracking testing. In this study, a network-based epidemic transmission model combined with a testing mechanism was proposed to study the role of testing in epidemic control. The aim of this study was to determine how testing affects the spread of epidemics and the daily testing volume needed to control infectious diseases.

Methods

We simulated the epidemic spread process on complex networks and introduced testing preferences to describe different testing strategies. Different networks were generated to represent social contact between individuals. An extended susceptible-exposed-infected-recovered (SEIR) epidemic model was adopted to simulate the spread of epidemics in these networks. The model establishes a testing preference of between 0 and 1; the larger the testing preference, the higher the testing priority for people in close contact with confirmed cases.

Results

The numerical simulations revealed that the higher the priority for testing individuals in close contact with confirmed cases, the smaller the infection scale. In addition, the infection peak decreased with an increase in daily testing volume and increased as the testing start time was delayed. We also discovered that when testing and other measures were adopted, the daily testing volume required to keep the infection scale below 5% was reduced by more than 40% even if other measures only reduced individuals’ infection probability by 10%. The proposed model was validated using COVID-19 testing data.

Conclusions

Although testing could effectively inhibit the spread of infectious diseases and epidemics, our results indicated that it requires a huge daily testing volume. Thus, it is highly recommended that testing be adopted in combination with measures such as wearing masks and social distancing to better manage infectious diseases. Our research contributes to understanding the role of testing in epidemic control and provides useful suggestions for the government and individuals in responding to epidemics.
Literature
1.
2.
3.
4.
Reid S, Reid C, Vermund S. Antiretroviral therapy in sub-saharan africa: adherence lessons from tuberculosis and leprosy. Int J STD AIDS. 2004; 15(11):713–6.PubMedCrossRef
5.
Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH. From malaria control to eradication: The who perspective. Trop Med Int Health. 2009; 14(7):802–9.PubMedCrossRef
6.
7.
Sridhar S, To KK, Chan JF, Lau SK, Woo PC, Yuen K-Y. A systematic approach to novel virus discovery in emerging infectious disease outbreaks. J Mol Diagn. 2015; 17(3):230–41.PubMedCrossRef
8.
Chan JF, Sridhar S, Yip CC, Lau SK, Woo PC. The role of laboratory diagnostics in emerging viral infections: the example of the middle east respiratory syndrome epidemic. J Microbiol. 2017; 55(3):172–82.PubMedPubMedCentralCrossRef
9.
Perkins MD, Dye C, Balasegaram M, Bréchot C, Mombouli J-V, Røttingen J-A, Tanner M, Boehme CC. Diagnostic preparedness for infectious disease outbreaks. Lancet. 2017; 390(10108):2211–4.PubMedCrossRef
10.
Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, Zwahlen M, Senti G, Battegay M, Wilder-Smith A, et al. Covid-19 epidemic in switzerland: on the importance of testing, contact tracing and isolation. Swiss Med Wkly. 2020; 150(11-12):20225.
11.
Vermund SH. Control of hiv epidemic: improve access to testing and art. Lancet HIV. 2017; 4(12):533–4.CrossRef
12.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Antiretroviral therapy for the prevention of hiv-1 transmission. N Engl J Med. 2016; 375(9):830–9.PubMedPubMedCentralCrossRef
13.
Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou S-S, Anderson M, McCauley M, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of hiv-1 infection: results from the phase 3 hptn 052 randomised controlled trial. Lancet Infect Dis. 2014; 14(4):281–90.PubMedPubMedCentralCrossRef
14.
Rydevik G, Innocent GT, Marion G, Davidson RS, White PC, Billinis C, Barrow P, Mertens PP, Gavier-Widén D, Hutchings MR. Using combined diagnostic test results to hindcast trends of infection from cross-sectional data. PLoS Comput Biol. 2016; 12(7):1004901.CrossRef
15.
Hayes RJ, Donnell D, Floyd S, Mandla N, Bwalya J, Sabapathy K, Yang B, Phiri M, Schaap A, Eshleman SH, et al. Effect of universal testing and treatment on hiv incidence—hptn 071 (popart). N Engl J Med. 2019; 381(3):207–18.PubMedPubMedCentralCrossRef
16.
Abdool Karim SS. Hiv-1 epidemic control — insights from test-and-treat trials. N Engl J Med. 2019; 381(3):286–8.PubMedCrossRef
17.
Iwuji CC, Orne-Gliemann J, Larmarange J, Balestre E, Thiebaut R, Tanser F, Okesola N, Makowa T, Dreyer J, Herbst K, et al. Universal test and treat and the hiv epidemic in rural south africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV. 2018; 5(3):116–25.CrossRef
18.
Ortblad KF, Baeten JM, Cherutich P, Wamicwe JN, Wasserheit JN. The arc of hiv epidemics in sub-saharan africa: new challenges with concentrating epidemics in the era of 90–90–90. Curr Opin HIV AIDS. 2019; 14(5):354–65.PubMedPubMedCentralCrossRef
19.
Lightfoot MA, Campbell CK, Moss N, Treves-Kagan S, Agnew E, Dufour M-SK, Scott H, Sa’id AM, Lippman SA. Using a social network strategy to distribute hiv self-test kits to african american and latino msm. J Acquir Immune Defic Syndr. 2018; 79(1):38–45.PubMedCrossRef
20.
Mirandola M, Gios L, Joanna Davis R, Furegato M, Breveglieri M, Folch C, Staneková D, Nita I, Stehlíková D. Socio-demographic factors predicting hiv test seeking behaviour among msm in 6 eu cities. Eur J Public Health. 2017; 27(2):313–8.PubMed
21.
Mugabe D, Bhatt N, Carlucci JG, Gudo ES, Gong W, Sidat M, Moon TD. Self-reported non-receipt of hiv test results: A silent barrier to hiv epidemic control in mozambique. PLoS ONE. 2019; 14(10):0224102.CrossRef
22.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary hiv testing with immediate antiretroviral therapy as a strategy for elimination of hiv transmission: a mathematical model. Lancet. 2009; 373(9657):48–57.PubMedCrossRef
23.
24.
Ayoub HH, Awad SF, Abu-Raddad LJ. Use of routine hiv testing data for early detection of emerging hiv epidemics in high-risk subpopulations: a concept demonstration study. Infect Dis Model. 2018; 3:373–84.PubMedPubMedCentral
25.
Lorch L, Trouleau W, Tsirtsis S, Szanto A, Schölkopf B, Gomez-Rodriguez M. A spatiotemporal epidemic model to quantify the effects of contact tracing, testing, and containment. 2020. arXiv preprint arXiv:2004.07641.
26.
Scarselli D, Budanur NB, Hof B. Catastrophic failure of outbreak containment: Limited testing causes discontinuity in epidemic transition. 2020. arXiv preprint arXiv:2006.08005.
27.
Ng WL. To lockdown? when to peak? will there be an end? a macroeconomic analysis on covid-19 epidemic in the united states. J Macroecon. 2020; 65:103230.PubMedPubMedCentralCrossRef
28.
Berger DW, Herkenhoff KF, Mongey S. An seir infectious disease model with testing and conditional quarantine. Technical report, National Bureau of Economic Research. 2020.
29.
Aronna MS, Guglielmi R, Moschen LM. A model for covid-19 with isolation, quarantine and testing as control measures. 2020. arXiv preprint arXiv:2005.07661.
30.
Kolumbus Y, Nisan N. On the effectiveness of tracking and testing in seir models. 2020. arXiv preprint arXiv:2007.06291.
31.
Verma V, et al. Study of lockdown/testing mitigation strategies on stochastic sir model and its comparison with south korea, germany and new york data. 2020. arXiv preprint arXiv:2006.14373.
32.
33.
Villela DA. Imperfect testing of individuals for infectious diseases: Mathematical model and analysis. Commun Nonlinear Sci Numer Simul. 2017; 46:153–60.CrossRef
34.
Burstyn I, Goldstein ND, Gustafson P. It can be dangerous to take epidemic curves of covid-19 at face value. Can J Public Health. 2020; 111(3):397–400.PubMedCrossRefPubMedCentral
35.
Pastor-Satorras R, Castellano C, Van Mieghem P, Vespignani A. Epidemic processes in complex networks. Rev Mod Phys. 2015; 87(3):925.CrossRef
36.
Catanzaro M, Boguná M, Pastor-Satorras R. Generation of uncorrelated random scale-free networks. Phys Rev E. 2005; 71(2):027103.CrossRef
37.
Holme P, Kim BJ. Growing scale-free networks with tunable clustering. Phys Rev E. 2002; 65(2):026107.CrossRef
38.
Barabási A-L, Albert R. Emergence of scaling in random networks. Science. 1999; 286(5439):509–12.PubMedCrossRef
39.
Colizza V, Barrat A, Barthelemy M, Valleron A-J, Vespignani A. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PLoS Med. 2007; 4(1):13.CrossRef
40.
Balcan D, Gonçalves B, Hu H, Ramasco JJ, Colizza V, Vespignani A. Modeling the spatial spread of infectious diseases: The global epidemic and mobility computational model. J Comput Sci. 2010; 1(3):132–45.PubMedPubMedCentralCrossRef
41.
42.
43.
Wu JT, Leung G, Leung K. Nowcasting and forecasting the potential domestic and international spread of the 2019-ncov outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; 395(10225):689–97.PubMedPubMedCentralCrossRef
44.
45.
Pratomo H. From social distancing to physical distancing: A challenge forevaluating public health intervention against covid-19. Kesmas. 2020; 15(2):60–3.
46.
Ahmed F, Zviedrite N, Uzicanin A. Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review. BMC Public Health. 2018; 18(1):518.PubMedPubMedCentralCrossRef
47.
Weng W, Ni S. Evaluation of containment and mitigation strategies for an influenza a pandemic in china. Simulation. 2015; 91(5):407–16.CrossRef
48.
Migliori GB, Nardell E, Yedilbayev A, D’Ambrosio L, Centis R, Tadolini M, Van Den Boom M, Ehsani S, Sotgiu G, Dara M. Reducing tuberculosis transmission: a consensus document from the world health organization regional office for Europe. Eur Respir J. 2019; 53(6):1900391.PubMedCrossRef
49.
Xiao J, Shiu EY, Gao H, Wong JY, Fong MW, Ryu S, Cowling BJ. Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings—personal protective and environmental measures. Emerg Infect Dis. 2020; 26(5):967.PubMedPubMedCentralCrossRef
50.
51.
Leung NH, Chu DK, Shiu EY, Chan K-H, McDevitt JJ, Hau BJ, Yen H-L, Li Y, Ip DK, Peiris JM, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 2020; 26(5):676–80.PubMedCrossRefPubMedCentral
52.
53.
Brault V, Mallein B, Rupprecht J-F. Group testing as a strategy for the epidemiologic monitoring of covid-19. 2020. arXiv preprint arXiv:2005.06776.
54.
Gebhard O, Hahn-Klimroth M, Parczyk O, Penschuck M, Rolvien M. Optimal group testing under real world restrictions. 2020. arXiv preprint arXiv:2004.11860.
55.
Kadri U. Variation of positiveness to enhance testing of specimens during an epidemic. 2020. arXiv preprint arXiv:2004.11753.
Metadata
Title
A network-based model to explore the role of testing in the epidemiological control of the COVID-19 pandemic
Authors
Yapeng Cui
Shunjiang Ni
Shifei Shen
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
COVID-19
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05750-9

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue

Research

Proposal for the use of echocardiography in bloodstream infections due to different streptococcal species

Research

Quantitative assessment of the effectiveness of joint measures led by Fangcang shelter hospitals in response to COVID-19 epidemic in Wuhan, China

Research article

Use of monitoring indicators in hospital management of antimicrobials

Research article

Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™

Case report

A case report of streptococcal toxic shock syndrome caused by Streptococcus mitis in a healthy adult

Research

Risk factors and biofilm formation analyses of hospital-acquired infection of Candida pelliculosa in a neonatal intensive care unit
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits